David Nutt

Awakn Life Sciences Announces the Addition of Renowned Substance Addiction Researcher Professor Barbara Mason to Its Clinical Advisory Board

Thursday, July 22, 2021 - 1:00pm

Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - July 22, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board.
  • Prof. Mason will join the Clinical Advisory Board which, Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Ann Mithoefer, Dr. Michael Mithoefer and Prof. Matt Johnson all currently sit on.
  • Professor Nutt commented; Professor Mason is another world-leading addition to an already stellar scientific advisory board.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering medicine to better treat Addiction.

Awakn Life Sciences Appoints Addiction Expert Prof. David Nutt as Chief Research Officer

Thursday, June 24, 2021 - 12:00pm

Prof. Nutt Will Drive Progression of a Pipeline of New Psychedelic Medicines, Helping to Define a Clear Development Pathway to Treat Addiction Through Psychedelic Medicines

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - June 24, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering psychedelic medicine to treat Addiction, announced today that globally renowned neuroscientist and addiction researcher, Prof. David Nutt, has joined its executive team as Chief Research Officer.
  • Prof. Nutt will work closely with Dr. Shaun McNulty, Awakn's Chief Scientific Officer, who leads Awakn's Pre-Clinical stage and Clinical stage research and development programs.
  • Professor David Nutt commented, "I am delighted to take on the role of Chief Research Officer in this exciting new biotechnology company that promises to revolutionise the treatment of addictions.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations; researching, developing, and delivering psychedelic medicine to better treat Addiction.

Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

Tuesday, March 9, 2021 - 12:00pm

Prof. Nutt appointed Head of Research to Lead Awakn's Next-Gen Psychedelic Molecule Development

Key Points: 
  • In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead Awakn's next generation psychedelic molecule development programme.
  • Anthony Tennyson, CEO Awakn Life Sciences, commented, "This is another great step forward for Awakn.
  • David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep.
  • Nutt was a member of the Committee on Safety of Medicines and was President of the European College of Neuropsychopharmacology.

Khiron to be Exclusive Latin American Provider to Project Twenty21, Europe's Largest Medical Cannabis Study with 20,000 Patients

Tuesday, November 19, 2019 - 5:01am

Project Twenty21, Europe's first and biggest national medical cannabis registry, was launched on November 7, 2019 at the Royal College of Psychiatrists in London.

Key Points: 
  • Project Twenty21, Europe's first and biggest national medical cannabis registry, was launched on November 7, 2019 at the Royal College of Psychiatrists in London.
  • Leading the project, Professor David Nutt from the UK's leading independent scientific body Drug Science commented: "Medical cannabis is still out of reach for far too many.
  • Project Twenty21 has the support of The Royal College of Psychiatrists, The British Pain Society, the United Patients Alliance, patients, peers and medical cannabis campaigners.
  • About Khiron Life Sciences Corp.
    Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

Khiron to be Exclusive Latin American Provider to Project Twenty21, Europe's Largest Medical Cannabis Study with 20,000 Patients

Tuesday, November 19, 2019 - 5:01am

Project Twenty21, Europe's first and biggest national medical cannabis registry, was launched on November 7, 2019 at the Royal College of Psychiatrists in London.

Key Points: 
  • Project Twenty21, Europe's first and biggest national medical cannabis registry, was launched on November 7, 2019 at the Royal College of Psychiatrists in London.
  • Leading the project, Professor David Nutt from the UK's leading independent scientific body Drug Science commented: "Medical cannabis is still out of reach for far too many.
  • Project Twenty21 has the support of The Royal College of Psychiatrists, The British Pain Society, the United Patients Alliance, patients, peers and medical cannabis campaigners.
  • About Khiron Life Sciences Corp.
    Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.